J-Pharma (520A) Stock Overview

J-Pharma Co., Ltd. is engaged in drug discovery and development, focusing on amino acid transporters as drug targets. More details

520A fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Has not reported any financial data

Shares are highly illiquid

Does not have a meaningful market cap (¥12B)

520A Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View Stock Community

Unicycive Therapeutics

Looking to be second time lucky with a game-changing new product

Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more

5.2k

US$21.53

69.2% undervalued

stuart_roberts's

Fair Value

Profit Margin

20%

Future PE

27x

Price in 2030

US$34.67

J-Pharma Co., Ltd. Competitors

Price History & Performance

Summary of share price highs, lows and changes for J-Pharma
Historical stock prices
Current Share Price	JP¥730.00
52 Week High	JP¥809.00
52 Week Low	JP¥685.00
Beta	0
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	4.29%

Recent updates

Shareholder Returns

	520A	JP Pharmaceuticals	JP Market
7D	n/a	1.1%	0.7%
1Y	n/a	21.4%	28.8%

Return vs Industry: Insufficient data to determine how 520A performed against the JP Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how 520A performed against the JP Market.

Price Volatility

Is 520A's price volatile compared to industry and market?
520A volatility
520A Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	5.1%
Market Average Movement	4.7%
10% most volatile stocks in JP Market	9.3%
10% least volatile stocks in JP Market	2.3%

Stable Share Price: 520A's share price has been volatile over the past 3 months compared to the JP market.

Volatility Over Time: Insufficient data to determine 520A's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2005	n/a	Max Yoshitake	www.j-pharma.com

J-Pharma Co., Ltd. is engaged in drug discovery and development, focusing on amino acid transporters as drug targets. The company researches and develops drugs targeting solute carrier (SLC) transporters, with emphasis on the LAT1 amino acid transporter. It is developing several compounds for various medical indications, including JPH034 for central nervous system demyelinating diseases and multiple sclerosis.

J-Pharma Co., Ltd. Fundamentals Summary

How do J-Pharma's earnings and revenue compare to its market cap?
520A fundamental statistics
Market cap	JP¥12.27b
Earnings (TTM)	JP¥0
Revenue (TTM)	n/a

n/a

P/E Ratio

n/a

P/S Ratio

Is 520A overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
520A income statement (TTM)
Revenue	JP¥0
Cost of Revenue	JP¥0
Gross Profit	JP¥0
Other Expenses	JP¥0
Earnings	JP¥0

Last Reported Earnings

n/a

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did 520A perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/03/27 08:42
End of Day Share Price	2026/03/27 00:00
Earnings	N/A
Annual Earnings	N/A

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

J-Pharma Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

J-Pharma Co., Ltd.TSE:520A Stock Report